SCHEMBL1067864

SCHEMBL1067864

CC1N(CCCCCC(=O)O)c2ccc(S(=O)(=O)O)cc2C1(C)C.[KH]

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
KDM4A O75164 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
RORC P51449 2/20 0.34
GAA P10253 2/20 0.34
ALDH1A1 P00352 3/20 0.33
TBXA2R P21731 1/20 0.33
GNRHR P30968 1/20 0.33
CYP26B1 Q9NR63 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23724052 0.99 APEX1 (0.36) APEX1SMN1; SMN2POLBMEN1KDM4A
SCHEMBL1065475 0.99 APEX1 (0.36) APEX1SMN1; SMN2POLBMEN1KDM4A
Bromide SCHEMBL861823 0.98 APEX1 (0.35) APEX1SMN1; SMN2POLBMEN1KDM4A
SCHEMBL28395116 0.90 SMN1; SMN2 (0.36) SMN1; SMN2POLBMEN1KDM4AMAPT
SCHEMBL881399 0.87 APEX1 (0.34) APEX1SMN1; SMN2POLBRORCGAA
SCHEMBL1069437 0.84 SMN1; SMN2 (0.38) APEX1SMN1; SMN2POLBMEN1KDM4A
SCHEMBL6018477 0.84 MEN1 (0.35) SMN1; SMN2POLBMEN1KDM4AMAPT
SCHEMBL15137506 0.83 POLB (0.32) APEX1SMN1; SMN2POLBRORCGAA
SCHEMBL28249171 0.83 KMT2A (0.38) SMN1; SMN2POLBMEN1KDM4AMAPT
SCHEMBL2677869 0.83 MEN1 (0.36) SMN1; SMN2POLBMEN1KDM4AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1078023-B1 LUMINESCENT COMPOUNDS LUMINEX CORPORATION (US) 2011-01-05 EP disclosed
EP-1849837-A2 Luminescent compounds Terpetschnig, Ewald A. (US) 2007-10-31 EP disclosed
US-20030235846-A1 Luminescent compounds TERPTETSCHNIG, EWALD A. 2003-12-25 US disclosed
EP-1078023-A4 LUMINESCENT COMPOUNDS TERPETSCHNIG EWALD A (US) 2003-03-26 EP disclosed
US-6538129-B1 Luminescent compounds Terpetschnig, Ewald A. 2003-03-25 US disclosed
EP-1078023-A1 LUMINESCENT COMPOUNDS Terpetschnig, Ewald A. (US) 2001-02-28 EP disclosed
WO-1999051702-A1 LUMINESCENT COMPOUNDS TERPETSCHNIG EWALD A (US) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030235846-A1 Luminescent compounds CROCC, NR2E1, NDC1 APEX1 2373/4885SMN1; SMN2 3356/4885POLB 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.